摘要
目的:对人工肝结合131I治疗与内科常规治疗甲状腺功能亢进(甲亢)合并重症肝损害患者的临床疗效进行比较.方法:对近6年来我院40例甲亢合并重症肝损害患者的临床表现、实验室检查、治疗方式及预后进行回顾性分析,比较采用人工肝[方式有分子吸附再循环系统(molecula radsorbent recirculating system,MARS)、血浆置换]结合131I与内科常规治疗的疗效和预后.结果:人工肝组有25例患者,20例好转,5例病情恶化,内科常规治疗组共15例患者,6例好转,9例恶化,人工肝组好转率(80%)明显高于内科常规治疗组(40%),人工肝治疗能显著改善患者肝功能、甲状腺功能指标,缩短凝血酶原时间,提高治愈率.结论:甲亢合并重症肝损害病情复杂,治疗棘手,根据病情需要行人工肝治疗,在肝功能改善后行131I能明显改善预后,提高生存率,降低病死率.
AIM：To evaluate the clinical effect of artificialliver combined with 131I therapy versus conventional medical treatment in patients with hyperthyroidism and severe liver injury.METHODS：The clinical data for 40 patientswith hyperthyroidism and severe liver injurywho were treated at our hospital over the past 6years were retrospectively analyzed to comparethe efficacy of artificial liver combined with 131Itherapy versus conventional medical treatment.RESULTS：Twenty-five patients underwentartificial liver treatment,and of them 20 had aresponse and 5 had disease progression.Theresponse rate was 80%.Fifteen patients receivedconventional medical treatment,and of them 6had a response and 59 had disease progression,with a response rate of only 40%.Artif icial livertreatment significantly improved liver functionand thyroid function,shortened PT time and increased the cure rate.CONCLUSION：Artificial liver combined with131I therapy can signif icantly improve prognosis and reduce mortality in patients with hyperthyroidism and severe liver injury.
出处
《世界华人消化杂志》
CAS
北大核心
2011年第28期2983-2986,共4页
World Chinese Journal of Digestology
